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ABSTRACT
Metabolic Syndrome (MetS) is a growing public health concern worldwide. Individuals with MetS 
have an increased risk for cardiovascular (CV) disease and type 2 diabetes (T2D). These diseases – in 
part preventable with the treatment of MetS – increase the chances of premature death and pose a 
great economic burden to health systems. A healthy gut microbiota is associated with a reduction 
in MetS, T2D, and CV disease. Treatment of MetS with fecal microbiota transplantation (FMT) can be 
effective, however, its success rate is intermediate and difficult to predict. Because bacteriophages 
significantly affect the microbiota membership and function, the aim of this pilot study was to 
explore the dynamics of the gut bacteriophage community after FMT in MetS subjects. We 
performed a longitudinal study of stool bacteriophages from healthy donors and MetS subjects 
before and after FMT treatment. Subjects were assigned to either a control group (self-stool 
transplant, n = 3) or a treatment group (healthy-donor-stool transplant; n-recipients = 6, n- 
donors = 5). Stool samples were collected over an 18-week period and bacteriophage-like particles 
were purified and sequenced. We found that FMT from healthy donors significantly alters the gut 
bacteriophage community. Subjects with better clinical outcome clustered closer to the heathy 
donor group, suggesting that throughout the treatment, their bacteriophage community was more 
similar to healthy donors. Finally, we identified bacteriophage groups that could explain these 
differences and we examined their prevalence in individuals from a larger cohort of MetS FMT trial.
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Introduction
MetS is a growing public health concern, currently 
affecting approximately one-third of people in the 
US and in several countries worldwide.1–6 
Diagnosis of MetS is based on the presence of 
three of the following manifestations: high waist 
circumference, insulin resistance, high blood pres-
sure, high plasma triglyceride levels in blood, and 
low high-density lipoprotein cholesterol (HDL).7 
Obesity is an important risk factor for MetS, since 
approximately 75% of the obese individuals have a 
metabolic disorder. However, 40% of the lean indi-
viduals are also metabolically unhealthy.7,8 
Individuals with MetS have an increased risk of 
developing T2D, CV disease, and nonalcoholic 
fatty liver disease.1,2,7,8 CV disease alone is the 
leading cause of death worldwide and, overall, indi-
viduals with MetS are four times more likely of 
dying from CV disease than otherwise healthy peo-
ple, and twice more likely to die from premature 
death.5,9 Overall, the health cost of MetS has been 
estimated in the billions of dollars in the US alone, 
being approximately 20% higher in MetS subjects 
than in healthy individuals.5,10 Because treatment 
of MetS can significantly reduce the risk of devel-
oping any of these diseases, understanding MetS 
etiology, and developing successful treatments is 
needed.
The composition and structure of the gut micro-
bial community has been associated with CV dis-
ease, obesity, diabetes, and MetS.11 Changes in the 
microbial community can affect the human host 
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through inappropriate activation of the immune 
system, reduced production of beneficial metabo-
lites for the human host, and reduced production 
stimulation of mammalian peptides necessary for 
glucose homeostasis.11,12 Moreover, specific bacter-
ial species have been linked to either MetS or a 
healthy state.13,14 For instance, certain Prevotella, 
Lactobacillus, and Bacteroides species are associated 
with insulin resistance – one of the hallmarks of 
MetS. On the other hand, Akkermansia municiphila 
and Faecalibacterium prausnitzii are associated 
with increased insulin sensitivity.
Manipulation of the gut microbiota by fecal 
microbial transplantation (FMT) is a promising 
approach for examining the clinical effects in 
response to restoration of healthy gastrointestinal 
conditions.15 For example, it has been well estab-
lished that the treatment of recurrent Clostridium 
difficile infections (CDI) with FTM is highly 
effective.13 However, success rate of FMT in other 
gastrointestinal diseases is highly variable.16,17 We 
previously showed that transplantation of healthy 
lean-donor fecal microbiota into MetS subjects 
improves peripheral insulin sensitivity based on a 
significant increase in the glucose disappearance 
rate (Rd).14,18 However, this effect only lasted 
approximately six weeks and only 65% of the sub-
jects that received a transplant from a healthy 
donor showed a clinical improvement (indicated 
by >10% increase in glucose disappearance rate 
(Rd) in the first 6 weeks after treatment).14,18 Even 
though specific changes in the bacterial community 
composition were associated with a positive clinical 
outcome, it alone was not sufficient to explain the 
variation in patient response, underscoring the 
need for a greater understanding of the factors 
influencing MetS FMT success in order to improve 
clinical outcomes.14
Viruses of bacteria (bacteriophages, or simply 
phages), through bacterial predation and tem-
porary symbiosis with specific bacterial species, 
are one of the main drivers of the structure and 
function of their host community.19–23 While it 
has been suggested that phages play a role in the 
success of FMT in recurrent CDI,24 to our 
knowledge, the composition and structure of 
the phage community in subjects with MetS 
and their role in MetS-FMT has not been pre-
viously investigated. We present here a temporal 
analysis of the phage community of adults with 
MetS that underwent FMT treatment with either 
their own stool samples (FMT control treatment 
group) or samples from healthy donors (FMT 
treatment group) (Table S1).14 Within the treat-
ment group, both responders and non-respon-
ders to FMT treatment were examined. We 
investigated bacteriophages dynamics after treat-
ment and attempted to determine particular fea-
tures that could render MetS individuals more 
likely to respond to FMT treatment.
Results
Subjects and study design
The experimental design is summarized in 
Figure S1. Male, Caucasian, obese subjects with 
MetS were randomly assigned to one of two 
treatment FMT groups: control or treatment 
transplant (see Table S1 for subjects’ informa-
tion). The control group received their own pro-
cessed-stool fecal sample as a control for how 
the FMT procedure itself (bowel lavage followed 
by stool microbial community transplant) affects 
gut microbial community dynamics. The treat-
ment group received processed-stool fecal sam-
ple from healthy lean donors. Subjects did not 
receive antibiotic treatment prior to the FMT. 
Based on the prior known treatment outcome 
(65% success rate), subjects from the treated 
group were further divided into Responder and 
Non-responder sub-groups.14 In this pilot study, 
we perform a longitudinal analysis of phage fil-
trates from three controls subjects (C), three 
non-responders (N), three responders (R), and 
five healthy donors (D) to investigate the bacter-
iophage dynamics during FMT and determine 
whether there were differences in the phage 
community based on treatment. It is important 
to note that stool viral-filtrates are highly 
enriched in bacteriophage-like particles.25,26 
Hence, viral-like particles were isolated from 
stool viral-filtrates at week 0 (pre-FMT) from 
donors and recipients, and at weeks 3, 6, 12, 
and 18 post-FMT from recipients. DNA was 
extracted and deep-sequenced, generating a 
total of 46 metagenomes made up of 62 Gb of 
sequence data (Table S2).
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Diversity and richness of the viral community before 
and after FMT treatment
Sequences from phage enriched metagenomes were 
grouped together by individual (14-individuals’ 
metagenomes) and assembled to produce 28,869 
putative viral sequences >3,000 bp (contigs, see 
Material and Methods) (Table S2). Abundance of 
viral sequences in each individual time point was 
determined by read recruitment after normaliza-
tion for differences in sequencing depth (see 
Material and Methods). Within these 28,869 viral 
sequences (contigs > 3000bp), Homologous Viruses 
(HV) were identified and grouped together based 
on the Homologous Virus Diversity Index techni-
que (HVDI).27 HV groups constitute sequences 
that likely belong to the same or highly related 
viruses. It is important to note that HV groups 
will contain viruses transferred from donors to 
recipients, as well as viruses shared between sub-
jects. A total of 19,234 sequences were grouped into 
1,544 HV, whereas 9,635 could not be clustered and 
remained as singletons. Because singletons are 
unique to individuals, and thus do not provide 
information about inter-individual similarities, 
analysis was focused primarily on HV groups.
Previous results demonstrated that the bacterial 
diversity pre-FMT (W0, before FMT) in study sub-
jects was associated with FMT treatment outcome.-
14 Therefore, we examined the alpha-diversity of 
HV groups pre-FMT and post-FMT treatment. 
We determined phage richness (i.e. number of 
phage sequences) and calculated the Shannon- 
diversity index, which takes in account both rich-
ness and abundance of each viral sequence. Overall, 
there were no significant differences in viral rich-
ness pre-FMT (Richness; Donors 118 ± 55.89, 
Controls 162.3 ± 70.71; Treatment 113.5 ± 46.04). 
However, within the treatment group, the non- 
responders had reduced viral richness as compared 
to responders, which was maintained for all sub-
jects across most sampling timepoints (Figure S2A- 
B). Likewise, no significant differences in Shannon- 
diversity index pre-FMT between treatment groups 
were observed (Shannon; Donors 3.7 ± 0.35, 
Controls 3.67 ± 0.28, Treatment 3.23 ± 0.65). 
Differences in viral community richness between a 
donor and its recipient have also been shown to be 
associated with recovery in CDI subjects after 
FMT.24 However, in our study, we did not detect 
a significant difference (NΔR: −55.33, sd: 103.6); 
RΔR: 44.33, sd: 29.37; p-value = 0.1842) (Figure 
S2C). Overall, these results suggest that phage rich-
ness and Shannon-diversity index are highly vari-
able and not significantly different between healthy 
subjects, MetS subjects, or treatment groups.
To determine what type of viruses were present 
in healthy donors as compared to MetS subjects, 
viral sequences were taxonomically classified 
(Figure S3). Translated ORFs from viral contigs 
were compared by psiBLAST to the Phage 
Orthologous Groups database (POGs).28,29 
Overall, 12,668 viral contigs (n = 28,869, 44%) 
were classified as bacteriophages based on a POG 
match. This included 268 HV contigs that were 
classified at the rank order or less (n = 1,544, 
17%). As is common with viral sequences from 
the human gut, only a small fraction is similar to 
known bacteriophages.28 However, it is worth not-
ing that the viral sequences classified as bacterio-
phages in this study represent a large portion of the 
total viral community (40% of total reads per Kb 
per million-RPKM for classified HV groups). 
Moreover, based on prior microscopy studies, the 
remaining sequences are likely phage sequences as 
well.25,26 In all individuals, the classified phages 
were dominated by members of the Caudovirales 
order, specifically Siphoviridae and Podoviridae 
families. At lower taxonomic ranks, typical taxa 
that has been previously associated with human 
gut bacteriophages were detected.29
Phage transfer during FMT course
In order to gain insights into the impact of FMT 
treatment on the recipient’s original viral commu-
nity structure, regardless of taxonomic classifica-
tion, we investigated the transfer and 
establishment of bacteriophages before and after 
the fecal microbial transplant (Figures 1, 2). 
Conceptually, the viral community of treated 
MetS subjects before FMT treatment (pre-FMT or 
baseline) includes viruses that are present both in 
the healthy donor and in the recipient before treat-
ment (“shared viruses with healthy donor pre- 
FMT”), and viruses that are only detected in the 
MetS recipient (“viruses unique to MetS subjects 
pre-FMT”) (green and pink category, respectively, 
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in Figure 1a top panel). In the case of the controls, 
since they received their own stool samples, all the 
viruses found pre-FMT are viruses unique to MetS 
recipients (pink category in Figure 1a bottom 
panel).
After FMT treatment, the original community in 
the recipient will undergo changes that include: (i) 
changes in abundance profile of viruses found pre- 
FMT; (ii) in the treatment group only, introduction 
of “invading viruses” (viruses found in healthy 
donors pre-FMT, and in their respective recipients 
only after FMT); (iii) and appearance of newly- 
activated prophages or viruses that were present 
below the detection threshold in either the 
recipients or the donors (“new viruses”). Hence, 
in subjects from the treatment group, it is not 
possible to determine whether they come from the 
donor or from the recipient.
One of the main goals was to examine whether 
receiving a FMT treatment from a healthy donor 
could displace viruses found in MetS recipients pre- 
FMT that do not share any similarities with viruses 
from their respective healthy donors (“viruses 
unique to MetS subjects pre-FMT”- pink group in 
Figure 1). To determine whether this goal was 
accomplished, the cumulative relative abundance 
of the different viral categories, before and after 
FMT, was calculated (Figure 1b–e). In the control 
Figure 1. Changes in the viral community of MetS subjects after FMT. (a) Schematic representation of the composition of the viral 
community before and after FMT in recipients from the treatment group (top panel) and the control group (bottom panel). Individuals 
in the treatment group received the stool microbial community of a healthy donor (n=6). Individuals in the control group received their 
own stool microbial community (n=3). (b) Bar plots of the community structure after FMT in MetS subjects. Plots represent the 
cumulative relative abundance of the different viral categories in each individual at each timepoint (Before FMT treatment- W0 and 
after- W3, 6, 12, 18). (c, d, e) Changes through time in the different viral categories. The treatment group was further divided in 
responders (n=3) or non-responders (n=3) based on treatment outcome. Significance was determined through a mixed effect model to 
account for repeated measures and missing data points followed by Sidak’s multiple comparison test. Asterisks show adjusted p-values: 
* <0.05, **<0.005, ***<0.0005.
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subjects that received their own stool samples, the 
virus community present just prior to FMT was 
similar to the virus community post FMT treat-
ment (average cumulative abundance of “viruses 
unique to MetS subjects pre-FMT” W3-W18: 80% 
±4.6, Figure 1b,c). In contrast, in individuals who 
received stool treatment from healthy donors only 
35%±6.9 of the viral community was maintained 
between pre- and post FMT treatment (average 
cumulative abundance of “viruses unique to MetS 
subjects pre-FMT” W3-W18: 35%±6.9, Figure 1b, 
c). Overall, this data suggests that transplantation of 
an allogenic stool sample from a healthy donor 
significantly reduces the abundance of viruses 
unique to MetS subjects as compared to receiving 
a self-stool transplantation (mixed-effect model p- 
value<0.0001, Figure 1c). To investigate whether 
changes in the control group were greater than 
the expected variation of the virome over time, a 
similar analysis was performed on two untreated 
healthy individuals previously studied in our 
laboratory.28 In these individuals, the viral commu-
nity found in our initial timepoint was highly main-
tained 12 and 60 weeks later (98% and 95% 
cumulative abundance at W12 and W60, respec-
tively). This result is consistent with the literature 
and highlights the high stability of the gut viral 
community overtime. It also suggests that the tem-
poral changes observed in the control group are 
slightly higher than those expected due to temporal 
variation of the gut viral community (80%±4.6 vs 
95–98%). However, future studies should include a 
no-FMT group within the trial to serve as an inter-
nal control for temporal variation. Overall, these 
results suggest that FMT transplant treatment with 
a stool sample from a healthy individual signifi-
cantly reduces the presence of the recipient’s 
viruses that are not highly related to viruses from 
the donor’s viral community.
We investigated whether the reduction in 
“viruses unique to MetS subjects pre-FMT” in the 
treatment group was due to an increase in new 
viruses or an increase in donor-like viruses 
(Figure 1d,e). Analysis of the cumulative relative 
abundance of both categories suggests that there is 
a significant increase in new viruses after stool 
transplantation (25%±5.76 of the post-FMT viral 
community on average). This increase was signifi-
cantly higher in the treatment group three weeks 
after the transplant (10% vs 25% in control and 
treatment group, respectively; W3 adjusted p- 
value 0.034) (Figure 1d). This result suggests that 
in the treatment group viruses unique to MetS 
subjects pre-FMT were replaced by new viruses 
that were not originally present in either the healthy 
donors or control subjects at detectable 
abundances.
Next, we investigated whether there are differ-
ences in the donor-like viral community within 
subjects in the treatment group before and after 
treatment (Figures 1, 2, 3). First, we determined 
whether there were differences in the cumulative 
relative abundance of donor-like viruses (summa-
tion of relative abundance of donor-like bacterio-
phages). On average, 24%±8.7 of the community 
was taken by donor-like bacteriophages before 
FMT treatment (Figure 1e). After the FMT treat-
ment, the average increased slightly (37%±6.4, ns) 
and remained fairly stable within most individuals. 
No statistical differences were observed between 
treatment groups. We investigated the dynamics 
of donor-invading viruses and their ability to get 
established within the recipients (Figure 2). On 
average, 38 ± 14 donor-invading viruses (HV 
groups) could be detected in at least one time 
point after the FMT treatment (Figure 2a,b). 
There were no significant differences in the number 
or abundance of invading donor phage between 
treatment groups. It was noticeable that 
Responder 3 had a very low percentage of donor- 
like bacteriophages pre-FMT but that after treat-
ment multiple donor-invading phage were estab-
lished throughout the rest of the sampling time 
course (Figure 2a,c bottom right panel). With the 
exception of Responder 3 and Responder 1, there 
was no correlation between the relative abundance 
of donor invading phage originally in the donor 
compared to their relative abundance once estab-
lished in the recipient (mean R2 
adjusted = 0.18 ± 0.27). Interestingly, Non-respon-
der 2 showed a spike in donor-invading contigs 
12 weeks after FMT treatment. Some of these 
viruses were classified as Siphoviridae bacterio-
phages, suggesting that an unknown event could 
have led to an activation of prophages or latent 
viruses. Overall, these results show that the cumu-
lative relative abundances of donor-like viruses 
were not different among FMT treatment groups 
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Figure 2. Transfer and establishment of donor-invading viruses after FMT in the recipients gut viral community. (a) Cumulative relative 
abundance occupied by donor-invading bacteriophages. (b) Number of viruses (v) and their cumulative relative abundance (a) found in 
donors and recipients at each time point before and after FMT. C) Heatmaps of invading HV groups that take more than 0.05% of the 
community in at least one time point.
Figure 3. Analysis of donor-like HV viruses dynamics during the FMT time course. (a) Heatmap representation of log10 raw abundance 
of the 232 HV viruses that were shared between at least one healthy-donor recipient pair. Columns are organized based on average 
hierarchical clustering of Bray-Curtis dissimilarity and rows are organized based on complete hierarchical clustering of Euclidean 
distance. (b) Principal Coordinate Analysis of Bray-Curtis dissimilarity index of raw abundances of shared HV groups. Points represent 
individual time points. Number on top of the point represents week within the FMT course. (c) Bray-Curtis dissimilarities between 
healthy donors and their respective recipients.
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and that only a small percentage of donor-invading 
viruses was found in MetS subjects after FMT 
treatment.
We explored whether the donor viral commu-
nity profile could inform us about differences 
between treatment subgroups (Figure 3). We 
began by looking for viruses that were shared 
between a healthy donor and its respective MetS 
recipient. There were 232 HV groups shared by at 
least one pair (Figure 3a). Some of these HV groups 
were also found in MetS individuals that received a 
non-treatment FMT (controls), hence they were 
included in subsequent analysis. Principal 
Coordinate Analysis (PCO) was applied to Bray- 
Curtis distance matrix between treatment subjects 
and their donors at every time point (Figure 3b). 
Responders’ samples clustered significantly away 
from those of the non-responders (PERMANOVA 
centroid analysis R-N p = .003, Table S3). 
Interestingly, contrary to non-responders, the cen-
troid distance between responders and donors was 
not significantly different (N-D p = .003, R-D 
p = .354, Table S3). For clarity, the particular dis-
similarities between each healthy donor-MetS reci-
pient pair in the treatment group were separately 
graphed (Figure 3c). With the exception of 
Responder 3, all non-responders were very dissim-
ilar to their donors through time. Importantly, 
Responder 3 dissimilarity with its donor dropped 
sharply in the first weeks after treatment. Within 
the non-responder group, dissimilarities with the 
donor remained high up to six weeks post-treat-
ment. Overall, these results indicate that even if 
responders and non-responders have a similar frac-
tion of their community occupied by donor-like 
viruses, their relative abundance profile is more 
similar between responders and their donors than 
between non-responders and their donors.
Identification of phage groups enriched within 
treatment groups and their relationship with clinical 
outcome measures
Since there were differences between treatment 
subgroups (responders vs non-responders), we 
sought to identify specific bacteriophages enriched 
in these subgroups (Figure 4). To identify phage 
groups that explained most of the variation within 
the ordination analysis we applied similarity 
percentages analysis (SIMPER). From the 232 
donor-like HV groups used for the PCO analysis 
(Figure 3b), there were 22 HV groups that contrib-
uted significantly to separate treatment groups 
(simper permutation analysis p-value<0.05, Figure 
4a). From these, there was a subset of 10 HV groups 
that were mostly absent in non-responders pre- 
FMT but were found at high levels in responders. 
The only responder that did not harbor these HV 
groups pre-FMT (Responder 3), acquired and 
maintained them after FMT treatment. None of 
the non-responders acquired these 10 HV groups. 
Five of these groups were previously classified as 
Caudovirales (lowest rank classification). To con-
firm the presence and absence of these 
Caudovirales HV groups, we performed q-PCR 
based analysis of three of these HV groups 39, 67, 
84 (Figure 4b, See Material and Methods). The 
three groups were detected in responders and 
their donors pre-FMT (Figure 4b) and through- 
out the FMT time course. The same viral sequences 
were not detected in any of the viral DNA from the 
3 non-responders.
Next we determined whether there was any cor-
relation between the abundance of the 3 tested HV 
bacteriophages with clinical outcome measures. In 
the original FMT trial, subjects within the treat-
ment group were separated in responders and 
non-responders based on the increase in glucose 
disappearance rate (% increase Rd) (Figure 4c) 14 A 
correlation analysis between the abundance of HV 
virus 39, 67, and 84 and the % increase in Rd in 
individuals from the control and treatment group 
was performed. Specifically, we tested whether 
there was a relationship between these two variables 
at six weeks post-FMT treatment (W6) because in 
the original trial differences in the %Rd increase 
between responders and non-responders were only 
significant up to six weeks after FMT.14 This ana-
lysis revealed that the abundance of HV39 and 84 
was significantly correlated with the percentage 
increase in Rd at six weeks post-FMT (p-value 
<0.05, adjusted R2 > 0.5 Figure 4d). There was a 
small but not significant correlation between HV67 
and this clinical outcome (p-value = 0.051, 
R2 = 0.4795). These results suggest that within the 
limits of this small pilot study we have identified 2 
bacteriophage groups that are associated with a 
relevant clinical outcome.
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Prevalence of bacteriophages enriched in treatment 
outcome groups among a larger set of MetS subjects 
before FMT treatment
Next, we wanted to determine the prevalence of 
these HV groups (HV39, 67, and 84) pre-FMT 
in a larger set of MetS subjects that had under-
gone FMT treatment (Figure 5a). To do this, we 
performed a q-PCR analysis in the 38 subjects 
from the FMT trial under study. This includes 
the 9 subjects used to initially identify the 
enriched HV groups, and 29 additional subjects 
(total n = 38).14 Previous results had shown that 
of the 26 subjects that had received FMT treat-
ment from a healthy donor, 17 of these subjects 
had shown clinical improvement after the FMT 
(65%), while the remaining 9 subjects did not 
show clinical improvement (35%).14 Testing of 
stool samples from these 26 subjects for the 
presence of these 3 bacteriophages revealed that 
12 subjects contained high levels of at least two 
of the three bacteriophages (average 2 × 105 
copies/μl) (Figure 5a). Consistently with what 
we found in our smaller subgroup, the majority 
of individuals that had high levels of these phage 
groups presented a clinical improvement (83% 
(10 true responders/12 subjects with high HV 
levels). In the initial treatment subjects that we 
examined, 100% of the subjects were devoid or 
contained low levels of these HV groups did not 
respond to the treatment. In contrast, the 
screening of the larger set of MetS subjects 
revealed that approximately 50% of the subjects 
that were devoid or contained low levels of these 
HV groups did respond to treatment (7 true 
responders/14 subjects with low HV levels). We 
did not determine whether these individuals 
acquired these HV groups immediately after 
FMT, similarly to Responder 3 in this study.
Figure 4. Identification of phage groups enriched in treatment outcome subgroups. (a) Heatmap representation of log10 raw 
abundance of the HV viruses that significantly contribute to separate treatment groups in the ordination space in Figure 4b (simper 
analysis with 1000 permutations, p-value <0.05). Columns are organized based on average hierarchical clustering of Bray-Curtis 
dissimilarity and rows are organized based on complete hierarchical clustering of Euclidean distance. (b) Detection of these HV groups 
in study subjects pre-FMT using a q-PCR based assay. C) Percentage increase in glucose disappearance rate (Rd) from study subjects in 
this pilot study. The value of one control individual was removed (See statistical analysis). D) Correlation analysis between phage 
enriched in responder groups and the increase in Rd rate in subjects six weeks after transplant.
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Receiver Operating Characteristic (ROC) analy-
sis revealed that none of the HV groups were a 
significant discriminant factor in predicting treat-
ment outcome (area under the curve p-value 
>0.05), even though HV-84, which had the highest 
adjusted R2 values in the Rd linear models, was 
almost significant (p-value = 0.0557) (Figure 5b). 
Combining the abundance of these three HV 
groups was not significant either. This is likely 
due to the high false-negative rate obtained in a 
larger MetS cohort. Overall, these results suggest 
that even though almost all subjects that presented 
high levels of these HV groups presented clinical 
improvement, the sensitivity of this assay is insuffi-
cient to use them as predictors for treatment 
outcome.
Discussion
The overall objective of this study was to investigate 
changes in the gut bacteriophage community in 
MetS subjects that undergo FMT treatment in a 
small pilot study. Our results indicate that the gut 
viral community undergoes significant changes 
after receiving FMT treatment (Figure 1). 
Interestingly, we identified differences between the 
viral communities present in responders vs. non- 
responders. In particular, we found that the dissim-
ilarity between the viral community shared by reci-
pients and their respective donors was greater in 
subjects that did not respond to treatment (either 
before or in the first weeks after FMT) (Figure 3). 
Within the virus groups that could explain most of 
the dissimilarities, we identified phage groups that 
were associated with the main clinical outcome 
variable (percentage increase in glucose disappear-
ance rate- Rd) (Figure 4). We investigated the pre-
valence of these HV phages in a larger set of MetS 
subjects that had undergone FMT treatment. We 
found that even though the majority of individuals 
that had high levels of these HV phages did show 
clinical improvement, these phage groups were not 
Figure 5. Prevalence of bacteriophages enriched in responder subjects in this study among a larger set of MetS subjects before FMT 
treatment. (a) HV abundance in cellular DNA extracted from stool samples of treatment subjects in Koote et al. FMT trial determined 
through q-PCR analysis. (b) ROC curves analysis of HV abundances pre-FMT. The area under the curve and its correspondent p-value 
determine the suitability for these HV groups to be used as predictors for treatment outcome.
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discriminant enough to use them as biomarkers for 
predicting treatment outcome (ROC p-value: 0.09, 
0.178, 0.056). Overall, these results are promising 
and should provide support for a more powered 
expanded FMT study.
Interest in the role of bacteriophages in the gut 
microbial community has increased.22,30 Evidence 
for the beneficial impact of gut bacteriophages in 
human health is emerging.20 We previously 
reported the existence of a healthy gut phageome 
(HGP) in healthy individuals that was less prevalent 
in subjects with inflammatory bowel disease 
(IBD).20 We did not find similar decreased preva-
lence of the HGP in MetS subjects, suggesting that 
changes in the HGP might be only characteristic of 
certain gastrointestinal diseases. Even though the 
beneficial symptoms of FMT treatment are gener-
ally attributed to the bacterial component of the 
transferred stool, it is likely that, in conjunction 
with bacteria, additional members of the microbial 
community such as bacteriophages or fungi contri-
bute to clinical improvement in treated subjects.31 
In a recent pilot study, transplantation of fecal 
filtrates (FFT) alone restored health in CDI 
patients.32 Fecal filtrates are highly enriched in 
bacteriophages, suggesting that FFT benefits may 
be at least partially attributed to bacteriophages. 
Interestingly, a recent study showed that certain 
viruses encode insulin-like peptides, which are suf-
ficient to stimulate insulin signaling, suggesting 
that specific viral features could contribute to 
health in MetS subjects.33 However, it is important 
to note that FFT can also induce disease symptoms, 
emphasizing the importance of a balanced phage 
community to maintain health.34
Analysis of the role of bacteriophages during 
FMT in other disease subjects has been reported 
(i.e. CDI and ulcerative colitis-UC).24,35–38 Zuo et 
al. reported that bacteriophages could influence the 
outcome of CDI-FMT.24 In this study, individuals 
with CDI presented lower Caudovirales-richness 
than healthy donors at pre-FMT. Following FMT 
treatment, a high relative abundance of healthy 
donors’ invading phage was significantly associated 
with treatment success.24 In patients with UC, dif-
ferences in richness of the bacteriophage commu-
nity before or after the transplant were not 
associated with treatment outcome.38 However, 
more specific differences were not investigated.38
In our study, there were not significant differ-
ences in bacteriophage community richness or 
diversity between treatment groups (healthy 
donors, MetS controls, MetS that received healthy 
donor FMT). Differences in total Caudovirales 
abundance between responders and non-respon-
ders were not detected either, and viruses from 
the Microviridae family were underrepresented. 
Additionally, the healthy donors’ invading phage 
profile was similar between treatment subgroups 
(responders vs non-responders), and no specific 
patterns of bacteriophage transfer based on viral 
family classification were identified.37 Instead, 
responders could be differentiated from non- 
responders based on the community structure, 
and the phage community of responders and 
donors had a greater overlap (Figure 3). 
Therefore, we hypothesized that MetS subjects 
with a less distorted phage community at pre- 
FMT are more likely to show clinical improvement. 
These differences likely arise from differences in 
disease etiology, suggesting that evidence of the 
impact of bacteriophages in a specific disease can-
not be extrapolated to other health conditions.
Changes in the phage community of recipients 
after recipients might arise from two different 
sources (Figure 1): (1) establishment of donor 
invading phages, and (2) changes in the recipient’s 
phage community profile. Invading phages can be 
extracellular donor phages that successfully find 
and infect a host in the recipient’s established 
microbial community or donor prophages that are 
transferred inside their ‘Trojan bacterial-horse’ 
(phage integrated in the bacterial host genome).37 
Similar to donor invading bacterial strains, donor 
invading phages can be transferred and maintained 
through time in the recipient, but typically consti-
tute a small percentage of the post-FMT phage 
community.39 Changes in the recipient’s phage 
community that is successfully established will be 
primarily due to activation of previously inactive 
recipient prophages, as well as an increase in the 
relative abundance of pre-FMT low-abundance 
phages. The biggest changes were seen in the profile 
of the bacteriophages that were unique to the MetS 
recipient, particularly when they received a healthy 
donor stool sample, suggesting that the new com-
munity and the donor-community are able to dis-
place these types of bacteriophages. Future studies 
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directed at the mechanism(s) of phage establish-
ment and the direct function that phage play during 
FMT treatment in shaping the function and struc-
ture of gut microbial community are warranted.
The main limitation of our study is the small sam-
ple size per group. Despite this limitation, we were 
able to determine that FMT treatment, in absence of 
previous antibiotic treatment, significantly changes 
the bacteriophage community of the recipients. 
However, changing the bacteriophage community is 
not sufficient to present a clinical improvement in all 
the individuals. This is not surprising, since there is 
evidence of an association between the bacteriophage 
community structure and certain diseases,40 but a 
causal effect remains to be proven. It will be important 
to determine the magnitude and specific features of 
the changes that are necessary to present a clinical 
improvement in different diseases. In the case of MetS 
syndrome, results from this pilot study should be 
validated in a larger number of subjects in order to 
unequivocally demonstrate that the bacteriophage 
community is associated with treatment outcome. 
Additionally, this study does not address bacterioph-
age-host dynamics. Differences in the interaction 
between bacteriophages and their host, for example, 
due to host availability, could explain why individuals 
such as Responder 3 sustained a more dramatic and 
successful establishment of donor-invading bacterio-
phages shortly after the FMT treatment. Whole-gen-
ome sequencing of both, the bacterial and 
bacteriophage community will shed light into phage- 
host dynamics during FMT treatment. An extended 
analysis could also be useful to identify more robust 
biomarkers suitable for predicting clinical outcomes. 
Finally, analysis of the compatibility between donor 
and recipient and its influence on the treatment out-
come using a greater number of FMT pairs could be 
highly informative in FMT clinical trial design.
Material and methods
Extended material and methods are available in 
supplemental data.
Sample source and selection
The FMT trial herein analyzed is described in detail 
in Kootte et al.14 In brief, male, omnivorous, 
Caucasian, obese subjects with MetS were enrolled 
in a FMT clinical trial to test the efficacy of FMT 
treatment to treat MetS (see Table S1 from Kootte 
et al. for all subjects’ characteristics14). In this trial, 
subjects were randomly assigned to the control 
treatment group (self-stool microbial transplant) 
and treatment (healthy donor stool microbial trans-
plant) treatment group. The control group informs 
of the dynamics associated with the fecal transplant 
procedure alone (bowel lavage followed by stool 
microbial community transplant), regardless of 
the stool microbial community source. A portion 
of each of the individual fecal samples was frozen 
for analysis of the microbial and bacteriophage 
community. The remaining sample content was 
prepared for transplantation by homogenization 
in 500cc of 0.9% sterile saline and filtration through 
a metal sieved. Within 6 hours of fecal sample 
preparation, subjects received a bowel lavage, fol-
lowed by the transfer of the processed stool. A key 
clinical outcome measure was the rate of glucose 
disappearance (Rd rate), which is a measure of 
insulin sensitivity. For the small pilot study 
described here, a subset of these subjects was 
selected to analyze the bacteriophage community 
dynamics. Three individuals from the control treat-
ment group were randomly selected (see Table S1 
for subjects’ characteristics in this study). 
Additionally, six individuals from the treatment 
group, three with the highest and three with lowest 
Rd rate were selected as responders and non- 
responders, respectively.
Virus purification and sequencing data process
Fecal samples (1 g) were resuspended in SM buffer, 
span down and subsequently filtered through 2 and 
8-micron filters (fecal filtrates) (See extended mate-
rial and methods in supplementary data). After 
DNAse treatment, DNA from viral fecal filtrates 
was extracted and the DNA was sequenced using 
HiSeq Illumina technology (Table S2). Reads were 
quality trimmed with trimmomatics [33] and 
assembled with IDBA.41 Reads from individual 
study subjects were pooled together and assembled. 
It is important to note that metagenomes from 
different individuals were not pooled together at 
any time. In total, 14 assemblies were generated: 9 
cross-assemblies for subjects (3x autologous, 3x 
non-responders and 3x responders FMTs) and 5 
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single-subject assemblies for each healthy donor. 
High-quality reads were de-duplicated. To normal-
ize for different sequencing depths between sam-
ples, reads from each metagenome were randomly 
subsampled at a constant depth of 1,367,462 reads 
per time point and these subsampled reads were 
used to mapped to the assembled contigs. Contig 
abundance was determined based on number of 
Reads Per (contig) Kb per Million reads (RPKM). 
Contigs with hits to 16S rDNA were eliminated. 
Efforts in removing bacterial contamination were 
discrete to avoid removing prophage sequences. 
Only contigs with >7RPKM (minimum RPKM in 
donors) were considered present.
Homologous virus (HV) identification
Assembled contigs > 3000 bp were used to deter-
mine HV groups. Specifically, an all-to-all BLASTn 
analysis was performed using these contigs and 
default parameters, except e-value was set to 1e-20 
and hsp-to-query-ratio was 0.5.42,43 The resulting 
BLASTn file was parsed using network analysis to 
determine group membership.28,44
Taxonomic classification
ORFs were predicted with prodigal45 for all indivi-
dual viral contigs (n = 28,869) and compared to the 
POG database.28,29 Proteins longer than 100aa with 
less than 1% of their length in ambiguities were 
queried against the POGs database (PSI-BLAST 
default values except e-value set as <1e-5). Contigs 
that contain at least one taxa marker gene were 
classified based on Waller et al.28,29 When multiple 
sequences contained a taxa marker gene and were 
in the same HV group, their taxonomy was always 
concordant, therefore, their taxonomy was 
extended to all contigs from the group.
Ordination analysis
Bray-Curtis dissimilarity matrix was calculated 
using the Vegan R package,46 and PCO was carried 
out using LabDSV47 and the Vegan R package46 
respectively. Analysis of centroids was performed 
through PERmutational Multivariate ANalysis Of 
VAriance (PERMANOVA) using the Adonis func-
tion within the Vegan R package.48
Identification of HV groups that contribute to 
treatment outcome differences identification and 
analysis
HV groups that significantly separated responders 
from non-responders were identified using the dis-
similarity index generated with the SIMPER func-
tion from the vegan package in R, based on 
treatment group (donor, controls, non-responders 
and responders), using 1000 permutations.46 HV 
groups that separated treatment groups with a 
cumulative sum <0.7 and a p-value < 0.05 were 
selected.
qPCR analysis selected HV group
HV groups that separated treatment groups with a 
cumulative sum <0.7 and a p-value < 0.05 after 
SIMPER analysis, that were missing in the Non- 
responder groups (square in Figure 5a) and that 
were classified as Caudovirales were selected for 
further analysis (HV groups 39, 67, 84, 85 and 0). 
Because HV groups encompass at least 2 phage 
sequences (contigs) or more, individual contigs 
these HV groups (n-contigs = 1067) were 
extracted and assembled together within each 
HV group into a total of 425 contigs (Geneious 
assembly custom sensitivity settings; 1500 bp at 
90% identity).49 Reads were re-mapped to these 
contigs using bowtie2 and normalized based on 
RPKM (see sequencing data processing). Contigs 
were scored based on abundance and presence in 
responders, non-responders and donors to iden-
tify sequences suitable for qPCR analysis. First, the 
total RPKM per contig in all responders and 
donors, and separately in non-responders was cal-
culated. Then, it was multiplied, respectively, by 
the number of responders and donors (R-score) or 
non-responders (N-score) that had that contig. 
Subsequently, the R-score was divided by the N- 
score plus 1 and multiplied by the median number 
of reads in responders and donors, rendering the 
Score for each contig. The highest-scored contigs 
per HV group were visually inspected. Primers to 
conserved areas between subjects, POG genes 
when possible, were designed using Geneious.49 
Target sequences were amplified using q-PCR, 
both in total cellular DNA and in viral filtrate 
DNA. qPCR on viral DNA was done in 1:100 
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dilution of DNA material in triplicate using 
SsoAdvanced™ Universal SYBR® Green Supermix. 
qPCR on cellular DNA was done in 20 ng of DNA 
material in triplicate SsoAdvanced™ Universal 
SYBR® Green Supermix. Copies per ul were deter-
mined using standard curves.
Statistical analysis
Differences in viral diversity and richness pre-FMT 
and through time were determined using t-test and 
mixed effect model analysis to account for repeated 
measures and missing data points followed by Sidak’s 
multiple comparison test using PRISM software. 
Differences in the cumulative relative abundances 
of different viral community groups (e.g. “viruses 
unique to MetS subjects pre-FMT”) was determined 
using a mixed effect model analysis to account for 
repeated measures and missing data points using 
PRISM software. Analysis of centroids after ordina-
tion analysis was performed through permutation 
analysis using Adonis within the Vegan R package.48 
Linear models of the HV abundance and Rd rate 
were performed in using the lm function in R. For 
this analysis, control subject 1 was removed because 
its % increase in Rd value was a great outlier even 
though its Rd values were lower than almost all sub-
jects in the trial (See Figure 2 in Kootte et al. 201714). 
Statistical differences in the HV abundance after q- 
PCR analysis were determined using the non-para-
metric Mann–Whitney test in PRISM software. ROC 
curve analysis was performed using PRISM software.
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